ASCO Annual Meeting
ASCO Annual Meeting
Source/Disclosures
Source:

Siena S, et al. Abstract 4000. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Daiichi Sankyo Co. Ltd. funded this study. Siena reports consultant/advisory roles with Amgen, Bayer, Bristol-Myers Squibb, CheckmAb, Clovis Oncology, Daiichi Sankyo, Incyte, Merck, Novartis, Roche/Genentech and Seattle Genetics; research funding from MSD Oncology; stock and other ownership interests in Guardant Health and Myriad Genetics; travel, accommodations or expenses from Amgen, Bayer and Roche; and patents, royalties and other intellectual property from Amgen. Please see the abstract for all other researchers’ relevant financial disclosures.
May 30, 2020
2 min read
Save

HER2-targeted therapy shows antitumor activity in metastatic colorectal cancer

Source/Disclosures
Source:

Siena S, et al. Abstract 4000. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Daiichi Sankyo Co. Ltd. funded this study. Siena reports consultant/advisory roles with Amgen, Bayer, Bristol-Myers Squibb, CheckmAb, Clovis Oncology, Daiichi Sankyo, Incyte, Merck, Novartis, Roche/Genentech and Seattle Genetics; research funding from MSD Oncology; stock and other ownership interests in Guardant Health and Myriad Genetics; travel, accommodations or expenses from Amgen, Bayer and Roche; and patents, royalties and other intellectual property from Amgen. Please see the abstract for all other researchers’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Trastuzumab deruxtecan demonstrated durable benefit among patients with HER2-expressing metastatic colorectal cancer, according to findings of the phase 2 DESTINY-CRC01 study presented during the ASCO20 Virtual Scientific Program.

Interstitial lung disease appeared to be an important risk that requires careful recognition and intervention, researchers noted.

Trastuzumab deruxtecan [Enhertu; AstraZeneca, Daiichi Sankyo] is a novel antibody-drug conjugate composed of three components — an anti-HER2 immunoglobin G1 monoclonal antibody, a tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload. Early studies have shown promising activity in advanced HER2-expressing tumors,” Salvatore Siena, MD, professor of medical oncology at Università degli Studi di Milano and director of Niguarda Cancer Center at Grande Ospedale Metropolitano Niguarda in Italy, said during a presentation.

Salvatore Siena
Salvatore Siena

The open-label, multicenter DESTINY-CRC01 trial included 78 patients (median age, 58.5 years; range, 27-79; 52.6% men) with HER2-expressing RAS wild-type metastatic colorectal cancer (89.7% left colon or rectum cancer). All patients received at least two prior lines of treatment (median prior lines, 4; range, 2-11), and 20.5% had prior anti-HER2 therapy. Researchers excluded patients who had a prior history of or current/suspected interstitial lung disease.

The study consisted of three cohorts. Cohort A included 53 patients with immunohistochemical 3-positive or immunohistochemical 2-positive/in situ hybridization-positive disease; cohort B included seven patients with immunohistochemical 2-positive/ in situ hybridization-negative disease; and cohort C included 18 patients with immunohistochemical 1-positive disease.

All patients received 6.4 mg/kg trastuzumab deruxtecan IV every 3 weeks.

Confirmed objective response rate in cohort A served as the primary endpoint. Disease control rate, duration of response, PFS, OS and ORR in cohorts B and C served as secondary endpoints.

Median treatment duration was 3.5 months (95% CI, 2.1-4.3) overall and 4.8 months (95% CI, 3.9-5.8) in cohort A, with 38.5% of patients remaining on study treatment (41% discontinued due to disease progression and 9% due to clinical progression).

Results showed a confirmed ORR in cohort A of 45.3% (95% CI, 31.6-59.6). This included one complete response and 23 partial responses. Twenty patients achieved stable disease, for a disease control rate of 83% (95% CI, 70.2-91.9).

Median duration of response was not reached.

Researchers observed no responses in cohorts B or C.

Among those who received prior anti-HER2 therapy, researchers observed an ORR of 43.8% (95% CI, 19.8-70.1).

Median PFS was 6.9 months (95% CI, 4.1 to not reached) and median OS was not reached.

PAGE BREAK

Grade 3 or higher treatment-emergent adverse events occurred among 61.5% of patients. These included decreased neutrophil count (21.8%) and anemia (14.1%). Interstitial lung disease associated with study treatment was confirmed in 6.4% of patients.

Seven patients discontinued treatment as a result of treatment-related adverse events.

“We observed a safety profile consistent with what has been previously reported,” Siena said during the presentation. “These data demonstrate the potential of trastuzumab deruxtecan as a treatment option for patients with advanced HER2-positive metastatic colorectal cancer.” – by Jennifer Southall

Reference:

Siena S, et al. Abstract 4000. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.

Disclosures: Daiichi Sankyo Co. Ltd. funded this study. Siena reports consultant/advisory roles with Amgen, Bayer, Bristol-Myers Squibb, CheckmAb, Clovis Oncology, Daiichi Sankyo, Incyte, Merck, Novartis, Roche/Genentech and Seattle Genetics; research funding from MSD Oncology; stock and other ownership interests in Guardant Health and Myriad Genetics; travel, accommodations or expenses from Amgen, Bayer and Roche; and patents, royalties and other intellectual property from Amgen. Please see the abstract for all other researchers’ relevant financial disclosures.